Cargando…
Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide
Alkylating agents have long played a central role in the adjuvant therapy of glioblastoma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered methylating agent with low systemic toxicity, during and after radiotherapy has markedly improved survival. Extensive in vitro and i...
Autores principales: | Bobola, Michael S., Kolstoe, Douglas D., Blank, A., Chamberlain, Marc C., Silber, John R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515961/ https://www.ncbi.nlm.nih.gov/pubmed/23230562 http://dx.doi.org/10.3389/fonc.2012.00176 |
Ejemplares similares
-
Nucleotide excision repair of abasic DNA lesions
por: Kitsera, Nataliya, et al.
Publicado: (2019) -
XPA Enhances Temozolomide Resistance of Glioblastoma Cells by Promoting Nucleotide Excision Repair
por: Dai, Weimin, et al.
Publicado: (2022) -
O(6)-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma
por: Bobola, Michael S., et al.
Publicado: (2014) -
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012) -
ALKBH1 Is Dispensable for Abasic Site Cleavage during Base Excision Repair and Class Switch Recombination
por: Müller, Tina A., et al.
Publicado: (2013)